ArticleJournal of medical virology2022
The variant-specific burden of SARS-CoV-2 in Michigan: March 2020 through November 2021.
Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Estimating the incidence of SARS-CoV-2 infections by jointly modelling seroprevalence, hospitalization and mortality data, February 2020 - January 2021, Belgium.Archives of public health = Archives belges de sante publique · 2026Article
- Disparities in SARS-CoV-2 Infection Among Arab Americans Living in Southeast Michigan.Journal of racial and ethnic health disparities · 2025Observational
- SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020-July 2022.American journal of epidemiology · 2025Article
- Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.Vaccines · 2025Review
- Racial and ethnic differences in COVID-19 infection and vaccine uptake across multiple waves of the pandemic in Southeast Michigan: a retrospective cohort study.Frontiers in public health · 2025Article
- Risk Factors for Community and Intrahousehold Transmission of SARS-CoV-2: Modeling in a Nationwide French Population-Based Cohort Study, the EpiCoV Study.American journal of epidemiology · 2024Article
- Corrigendum.Journal of medical virology · 2023Article
- Rapid transmission and tight bottlenecks constrain the evolution of highly transmissible SARS-CoV-2 variants.Nature communications · 2023Article
- SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients.Microbiology spectrum · 2022Article
- The variant-specific burden of SARS-CoV-2 in Michigan: March 2020 through November 2021.Journal of medical virology · 2022Article
- Rapid transmission and tight bottlenecks constrain the evolution of highly transmissible SARS-CoV-2 variants.bioRxiv : the preprint server for biology · 2022Article
Corrections and comments
- Erratum issuedCorrigendum.2023
Authors and funding
7 authors.
Funding
Abstract
Accurate estimates of the total burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to inform policy, planning, and response. We sought to quantify SARS-CoV-2 cases, hospitalizations, and deaths by age in Michigan. Coronavirus disease 2019 cases reported to the Michigan Disease Surveillance System were multiplied by age and time-specific adjustment factors to correct for under-detection. Adjustment factors were estimated in a model fit to incidence data and seroprevalence estimates. Age-specific incidence of SARS-CoV-2 hospitalization, death, vaccination, and variant proportions were estimated from publicly available data. We estimated substantial under-detection of infection that varied by age and time. Accounting for under-detection, we estimate the cumulative incidence of infection in Michigan reached 75% by mid-November 2021, and over 87% of Michigan residents were estimated to have had ≥1 vaccination dose and/or previous infection. Comparing pandemic waves, the relative burden among children increased over time. In general, the proportion of cases who were hospitalized or who died decreased over time. Our results highlight the ongoing risk of periods of high SARS-CoV-2 incidence despite widespread prior infection and vaccination. This underscores the need for long-term planning for surveillance, vaccination, and other mitigation measures amidst continued response to the acute pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.